NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
Clinical Trials
13 trialsNCT04515615 2024-09-19
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05602935 2023-09-28
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
The Second Affiliated Hospital of Fujian Medical University
Phase 2 Active not recruiting
NCT04609176 2023-04-21
Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Peking University
Phase 2 Unknown
NCT03755440 2022-09-21
PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.
Sun Yat-sen University
Phase 2 Completed
NCT05111444 2021-11-08
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Fudan University
Phase 2 Unknown
NCT05095636 2021-10-27
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Fudan University
Phase 2 Unknown
NCT04631757 2020-11-17
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04367025 2020-04-29
Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT04152889 2020-04-20
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
RenJi Hospital
Phase 2 Unknown
NCT04345783 2020-04-14
Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Phase 2 Unknown